Zhenming Liu

Title: Zhenming Liu: Innovator in Anti-Cancer Compounds

Introduction

Zhenming Liu is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceutical research, particularly in the development of anti-cancer compounds. His innovative work has the potential to impact cancer treatment significantly.

Latest Patents

Zhenming Liu holds a patent for an indazole hydrazide compound and its applications. This compound, represented in formula (I), features R selected from substituted alkyl, substituted alkenyl, and substituted phenyl. The substituents in the substituted alkyl and substituted alkenyl include phenyl and/or substituted phenyl, while R′ is selected from H and alkyl. Compared to prior art, this indole hydrazide compound serves as an integrin avβ3 receptor antagonist. It exhibits notable anti-prostate cancer activity and demonstrates a significant inhibitory effect on enzalutamide-resistant cell lines. Furthermore, this compound shows considerable anti-tumor angiogenesis activity, making it a candidate for the preparation of anti-tumor angiogenesis drugs to inhibit tumor angiogenesis. Zhenming Liu has 1 patent to his name.

Career Highlights

Zhenming Liu is currently employed at Beijing Baheal Chengchuang Pharmaceutical Research and Development Co., Ltd. His work at this company focuses on innovative drug development aimed at combating cancer. His research has garnered attention for its potential applications in clinical settings.

Collaborations

Zhenming Liu collaborates with notable colleagues, including Yimin Cui and Xiaocong Pang. Their combined expertise contributes to the advancement of pharmaceutical research and the development of new therapeutic strategies.

Conclusion

Zhenming Liu is a key figure in the field of pharmaceutical innovation, particularly in the development of anti-cancer compounds. His work has the potential to lead to significant advancements in cancer treatment and improve patient outcomes.